
    
      This study is a Interventional study. The target group was 3-18 years old, and the
      pathological stage was group II-IV recurrence or distant metastasis. A total of 48 patients
      were enrolled in this study. The treatment was radiotherapy combined with apatinib. The main
      outcome measures were ORR, DCR , OS , quality of life and drug safety. The main safety
      indicators were vital signs, laboratory indicators, adverse events (AE), and severe adverse
      events (SAE). This study is expected to be enrolled for 6 months.
    
  